

abiraterone tablet (YONSA)

Diagnosis Considered for Coverage:

- Metastatic castration-resistant prostate cancer (mCRPC)

Coverage Criteria:

For diagnoses above:

- Not being used with abiraterone (Zytiga), Xtandi, Nubeqa, or Erleada, **and**
- Patient unable to take abiraterone (Zytiga), **and**
- Dose does not exceed FDA label maximum, **and**
- One of the following androgen deprivation therapies:
 - Currently receiving a LHRH agonist: Zoladex (Goserelin), Vantas (histrelin), Lupron (leuprolide), Trelstar (triptorelin), **or**
 - Currently receiving a LHRH antagonist: Firmagon (degarelix), **or**
 - Patient had testes removed (bilateral orchiectomy).

Coverage Duration: one year

Effective Date: 11/29/2023